Citations

Clear

14 citation(s) found for "Kim, Jin Yong".

Single Cell Untargeted Lipidomics Using Liquid Chromatography Ion Mobility-Mass Spectrometry
Kim, Jin Yong , Ding, Husheng, Forsberg, Erica M. , Meyer, S. , Barsch, Aiko , Pandey, Akhilesh , Byeon, Seul Kee , Kim, Jinyong , Meyer, Sven W , Pandey, Akhilesh , Byeon, Seul Kee , Mun, Dong‐Gi

Mayo Clinic

Journal of Proteome Research | February 14, 2025 | Volume: 24 | Issue: 4 | Pages: 1579-1585

10.1021/acs.jproteome.4c00658 | PMID 39950635 Get It

Development of a Multiplexed Sphingolipids Method for Diagnosis of Inborn Errors of Ceramide Metabolism
Byeon, Seul Kee , Wegwerth, Peter Jared, George, John Phillip, Oglesbee, Devin , Matern, Dietrich , Pandey, Akhilesh , Kim, Jinyong, Zenka, Roman, George, John P, Vairo, Filippo , Pandey, Akhilesh , Oglesbee, Devin , Byeon, Seul Kee , Kim, Jin Yong , Zenka, Roman M. , Vairo, Filippo Pinto e , Schultz, Matthew

Mayo Clinic

Clinical Chemistry | August 29, 2024 | Volume: 70 | Issue: 11 | Pages: 1366-1374

10.1093/clinchem/hvae115 | PMID 39206579 Get It

Abstract Background Sphingolipids play a crucial role in cellular functions and are essential components of cell membranes, signaling molecules, and lipid metabolism. In particular, ceramide is a key intermediate in sphingolipid metabolism and defects in ceramide metabolism can lead to various inborn errors of metabolism, making ceramides important targets for clinical screening and diagnosis. Detecting altered concentration patterns of sphingolipids is desirable for distinguishing related inborn errors of metabolism for diagnosis and treatment monitoring. Methods We developed a liquid chromatography-tandem mass spectrometry method with a pathway-oriented approach to focus on sphingolipids involved in ceramide metabolism. A total of 47 sphingolipids bearing different head groups and side chains were targeted. Precision/reproducibility, linearity, and spike recovery extraction efficiency tests were performed on plasma and serum samples from confirmed cases of sphingolipidosis. Results Linearity of the method showed the coefficient of determination (r2) for all standards to be >0.99 with a slope of 1.00 ± 0.01. Intra- and interday reproducibility of standards spiked into plasma and serum revealed a coefficient of variation <20%. Spike and recovery assessment showed recovery values of 80%–120% for all standards. Altered levels of sphingolipids from patients with hereditary sensory and autonomic neuropathy caused by pathogenic variants in SPTLC2 and hypomyelinating leukodystrophy related to variants in DEGS1 were detected, in agreement with trends reported in earlier studies confirming the utility of this pathway-centric method. Conclusions This method can serve as a useful tool to simultaneously monitor sphingolipids, enabling screening and diagnosis of inborn errors of ceramide metabolism.
A complement C4–derived glycopeptide is a biomarker for PMM2-CDG
Garapati, Kishore , Budhraja, Rohit , Saraswat, Mayank , Joshi, Neha , Sachdeva, Gunveen S. , Jain, Anu, Ligezka, Anna N. , Radenkovic, Silvia , Ramarajan, Madan Gopal , Udainiya, Savita, Raymond, Kimiyo , Lam, Christina , Edmondson, Andrew C. , Sarafoglou, Kyriakie , Larson, Nicholas B. , Kim, Jinyong, Edmondson, Andrew C , Larson, Nicholas B , Joshi, Neha S , Ramarajan, Madan G , Garapati, Kishore , Kim, Jin Yong , He, Miao , Larson, Austin , Freeze, Hudson H. , Schultz, Matthew , Kozicz, Tamás , Morava, Éva , Pandey, Akhilesh

Mayo Clinic

JCI Insight | April 7, 2024 | Volume: 9 | Issue: 7 | Pages: No page available

10.1172/jci.insight.172509 | PMID 38587076 Get It

BACKGROUND Diagnosis of PMM2-CDG, the most common congenital disorder of glycosylation (CDG), relies on measuring carbohydrate-deficient transferrin (CDT) and genetic testing. CDT tests have false negatives and may normalize with age. Site-specific changes in protein N-glycosylation have not been reported in sera in PMM2-CDG. METHODS Using multistep mass spectrometry–based N-glycoproteomics, we analyzed sera from 72 individuals to discover and validate glycopeptide alterations. We performed comprehensive tandem mass tag–based discovery experiments in well-characterized patients and controls. Next, we developed a method for rapid profiling of additional samples. Finally, targeted mass spectrometry was used for validation in an independent set of samples in a blinded fashion. RESULTS Of the 3,342 N-glycopeptides identified, patients exhibited decrease in complex-type N-glycans and increase in truncated, mannose-rich, and hybrid species. We identified a glycopeptide from complement C4 carrying the glycan Man 5 GlcNAc 2 , which was not detected in controls, in 5 patients with normal CDT results, including 1 after liver transplant and 2 with a known genetic variant associated with mild disease, indicating greater sensitivity than CDT. It was detected by targeted analysis in 2 individuals with variants of uncertain significance in PMM2 . CONCLUSION Complement C4–derived Man 5 GlcNAc 2 glycopeptide could be a biomarker for accurate diagnosis and therapeutic monitoring of patients with PMM2-CDG and other CDGs. FUNDING U54NS115198 (Frontiers in Congenital Disorders of Glycosylation: NINDS; NCATS; Eunice Kennedy Shriver NICHD; Rare Disorders Consortium Disease Network); K08NS118119 (NINDS); Minnesota Partnership for Biotechnology and Medical Genomics; Rocket Fund; R01DK099551 (NIDDK); Mayo Clinic DERIVE Office; Mayo Clinic Center for Biomedical Discovery; IA/CRC/20/1/600002 (Center for Rare Disease Diagnosis, Research and Training; DBT/Wellcome Trust India Alliance)
Impact of statins based on high-risk plaque features on coronary plaque progression in mild stenosis lesions: results from the PARADIGM study
Sung, Ji Min , Lee, Byoung Kwon , Lin, Fay Y. , Hadamitzky, Martin , Kim, Yong‐Jin , Andreini, Daniele , Pontone, Gianluca , Chun, Eun Ju , Cademartiri, Filippo , Maffei, Erica , Marques, Hugo , Leipsic, Jonathon , Choi, Jung Hyun , Virmani, Renu , Samady, Habib , Chinnaiyan, Kavitha M. , Stone, Peter H. , Berman, Daniel S. , Shaw, Leslee J. , Min, James K. , Chang, Hyuk‐Jae , Cademartiri, Filippo , Virmani, Renu , Chang, Hyuk-Jae , Park, Hyung‐Bok , Arsanjani, Reza , Heo, Ran , Conte, Edoardo , Budoff, Matthew J. , Gottlieb, Ilan , Gonçalves, Pedro de Araújo , Lee, Sang‐Eun , Shin, Sanghoon , Narula, Jagat , Bax, Jeroen J.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | May 26, 2023 | Volume: 24 | Issue: 11 | Pages: 1536-1543

10.1093/ehjci/jead110 | PMID 37232393 Get It

Abstract Aims To investigate the impact of statins on plaque progression according to high-risk coronary atherosclerotic plaque (HRP) features and to identify predictive factors for rapid plaque progression in mild coronary artery disease (CAD) using serial coronary computed tomography angiography (CCTA). Methods and results We analyzed mild stenosis (25–49%) CAD, totaling 1432 lesions from 613 patients (mean age, 62.2 years, 63.9% male) and who underwent serial CCTA at a ≥2 year inter-scan interval using the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (NCT02803411) registry. The median inter-scan period was 3.5 ± 1.4 years; plaques were quantitatively assessed for annualized percent atheroma volume (PAV) and compositional plaque volume changes according to HRP features, and the rapid plaque progression was defined by the ≥90th percentile annual PAV. In mild stenotic lesions with ≥2 HRPs, statin therapy showed a 37% reduction in annual PAV (0.97 ± 2.02 vs. 1.55 ± 2.22, P = 0.038) with decreased necrotic core volume and increased dense calcium volume compared to non-statin recipient mild lesions. The key factors for rapid plaque progression were ≥2 HRPs [hazard ratio (HR), 1.89; 95% confidence interval (CI), 1.02–3.49; P = 0.042], current smoking (HR, 1.69; 95% CI 1.09–2.57; P = 0.017), and diabetes (HR, 1.55; 95% CI, 1.07–2.22; P = 0.020). Conclusion In mild CAD, statin treatment reduced plaque progression, particularly in lesions with a higher number of HRP features, which was also a strong predictor of rapid plaque progression. Therefore, aggressive statin therapy might be needed even in mild CAD with higher HRPs. Clinical trial registration ClinicalTrials.gov NCT02803411
Left atrial reservoir strain as a novel predictor of new-onset atrial fibrillation in light-chain-type cardiac amyloidosis
Choi, You‐Jung , Kim, Darae , Rhee, Tea-Min, Lee, Hyun‐Jung , Park, Jun‐Bean , Lee, Seung‐Pyo , Kim, Yong-Jin , Jeon, Eun‐Seok , Oh, Jae K. , Choi, Jin‐Oh , Kim, Hyung‐Kwan , Jeon, Eun-Seok , Kim, Hyung-Kwan , Rhee, Tea-Min, Chang, Sung‐A

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 14, 2023 | Volume: 24 | Issue: 6 | Pages: 751-758

10.1093/ehjci/jeac269 | PMID 36637873 Get It

Abstract Aims To investigate whether left arterial reservoir strain (LASr) could predict new-onset atrial fibrillation (NOAF) in patients with light-chain-type cardiac amyloidosis (ALCA). Methods and results This study enrolled 427 patients with CA from two tertiary centres between 2005 and 2019. LASr was measured using a vendor-independent analysis programme. The primary outcome was NOAF. A total of 287 patients with ALCA were included [median age 63.0 (56.0–70.0) years, 53.3% male]. The median LASr was 13.9% (10.5–20.8%). During the median follow-up of 0.85 years, AF occurred in 34 patients (11.8%). In the receiver operating characteristics curve analysis, the optimal cut-off of LASr for predicting NOAF was 14.4%. Patients with LASr ≤14.4% had a higher risk of NOAF than those with LASr >14.4% (18.1% vs. 5.1%, P < 0.010). In the multivariate analysis adjusting for confounding factors, including left arterial volume index and left ventricular global longitudinal strain (LV-GLS), higher LASr (%) was independently associated with lower risk for NOAF [adjusted hazard ratio (aHR): 0.936, 95% confidence interval (95% CI): 0.879–0.997, P = 0.039]. Furthermore, LASr ≤14.4% was an independent predictor for NOAF (aHR: 3.370, 95% CI: 1.337–8.492, P = 0.010). This remained true after accounting for all-cause death as a competing risk. Compared with Model 1 (LV-GLS) and Model 2 (LV-GLS plus LAVI), Model 3, including LASr showed a better reclassification ability for predicting NOAF (net reclassification index = 0.735, P < 0.001 compared with Model 1; net reclassification index = 0.514, P = 0.003 compared with Model 2). Conclusion LASr was an independent predictor of NOAF in patients with ALCA.
Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations
Saraswat, Mayank , Garapati, Kishore , Kim, Jin Yong , Budhraja, Rohit , Pandey, Akhilesh , Budhraja, Rohit , Kim, Jinyong, Pandey, Akhilesh , Kim, Jinyong , Garapati, Kishore

Mayo Clinic

PROTEOMICS | June 11, 2022 | Volume: 22 | Issue: 19-20 | Pages: No page available

10.1002/pmic.202200077 | PMID 35689797 Get It

AbstractPIK3CA is one of the most frequently mutated genes in human cancers, with the two most prevalent activating mutations being E545K and H1047R. Although the altered intracellular signaling pathways in these cells have been described, the effect of these mutations on their extracellular vesicles (EVs) has not yet been reported. To study altered cellular physiology and intercellular communication through proteomic analysis of EVs, MCF10A cells and their isogenic mutant versions (PIK3CA E545K and H1047R) were cultured and their EVs enriched by differential ultracentrifugation. Proteins were extracted, digested with trypsin and the peptides labeled with tandem mass tag (TMT) reagents and analyzed by liquid chromatography tandem mass spectrometry (LC‐MS/MS). Four thousand six hundred and fifty‐five peptides were identified from 579 proteins of which 522 proteins have been previously described in EVs. Relative quantitation revealed altered levels of EV proteins including several cell adhesion molecules. Mesothelin, E‐cadherin, and epithelial cell adhesion molecule were elevated in both mutant cell‐derived EVs. Markers of tumor invasion and progression like galectin‐3 and transforming growth factor beta induced protein were increased in both mutants. Overall, activating mutations in PIK3CA result in altered EV composition with characteristic changes associated with these hotspot mutations.
Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy
Park, Jun‐Bean , Lee, Heesun , Yoon, Yeonyee E. , Park, Hyo Eun , Choi, Su‐Yeon , Kim, Yong-Jin , Ommen, Steve R. , Kim, Hyung‐Kwan , Kim, Hyung-Kwan , Kim, Dahye , Hwang, In‐Chang , Yoon, Yeonyee Elizabeth , Cho, Goo‐Yeong , Han, Kyungdo

Mayo Clinic

European Journal of Preventive Cardiology | December 2, 2019 | Volume: 27 | Issue: 17 | Pages: 1849-1857

10.1177/2047487319889714 | PMID 31787021 Get It

Aims We sought to investigate the association of obesity and metabolic health status with the incidence of clinical hypertrophic cardiomyopathy (HCM) diagnosis in the general population. Our goal was to identify modifiable risk factors to attenuate clinical expression of HCM, enabling management evolution from a mostly passive strategy of risk stratification to a proactive strategy of modifying disease expression. Methods Using nationwide population-based data from the Korean National Health Insurance Service, 28,679,891 people who were free of prevalent HCM and who underwent health examinations between 2009 and 2015 were followed until 31 December 2016. The primary outcome was clinical HCM that was defined as incident diagnosis of HCM during the follow-up, after a blanking period of 12 months. Results Over a median follow-up of 5.2 years, 0.027% (n = 7851) of the study participants were diagnosed as incident HCM. The incidence rate per 1000 person-years was 0.059. A significant association was found between body mass index (BMI) and the incidence of clinical HCM after multivariate adjustment, with a hazard ratio per 1 kg/m2 increase in BMI of 1.063 (95% confidence interval 1.051–1.075). Metabolically unhealthy participants had a greater incidence of HCM than metabolically healthy participants, regardless of obesity status. The effect of BMI was more pronounced in several subgroups, including participants with no hypertension, those aged less than 65 years and men. Conclusion We found that individuals with obesity and/or metabolic abnormalities had a significantly higher incidence of clinical HCM diagnosis than their counterparts. Efforts to manage obesity and metabolic abnormalities may be important in modifying clinical expression of HCM.
Comparison of Disease-related Knowledge of Patients With Inflammatory Bowel Disease Between the West and the East Using an Updated Questionnaire (IBD-KNOW)
Kim, Jin Yong , Yoon, Hyuk , Hwang, Jun Seong , Yang, Suk‐Kyun , Park, Sang Hyoung , Loftus, Edward V. , Loftus, Edward V

Mayo Clinic

Journal of Clinical Gastroenterology | November 25, 2019 | Volume: 54 | Issue: 8 | Pages: 720-724

10.1097/mcg.0000000000001283 | PMID 31764490 Get It

Goals: The study aimed to compare the level and characteristics of disease-related knowledge of patients with inflammatory bowel disease (IBD) between the West and the East using an international version of a questionnaire regarding knowledge of inflammatory bowel disease (IBD-KNOW). Background: The authors recently developed a new questionnaire regarding IBD-KNOW, which showed excellent test characteristics in Korea. Study: The IBD-KNOW questionnaire was administered to 100 patients with IBD from tertiary referral hospitals in the United States and Korea. Scores were calculated and compared between US and Korean patients, and factors associated with high scores were analyzed. Results: A total of 196 (100 US and 96 Korean) patients with IBD completed the questionnaires. Analysis of the baseline characteristics revealed that male sex, smoking status, disease duration, history of IBD-related operations, family history of IBD, and use of corticosteroids or biologics were significantly different between US and Korean patients. The mean IBD-KNOW score was higher in US patients than in Korean patients (14.8 vs. 11.3; P<0.001). Multivariate analyses showed that a high IBD-KNOW score (top 25%) was associated with a positive family history of IBD (odds ratio, 2.90; P=0.025) in US patients with IBD and with the use of biologics (odds ratio, 3.65; P=0.008) in Korean patients with IBD. Conclusions: The IBD-KNOW questionnaire, an updated assessment tool of IBD-related knowledge, is simple, reliable, and available in various patient populations. IBD-KNOW can be used to identify the factors affecting the level of IBD-related knowledge to improve the quality of care in patients with IBD through a personalized approach.
Validation of the hypertrophic cardiomyopathy risk-sudden cardiac death calculator in Asians
Kim, Hyung‐Kwan , Lee, Sang‐Chol , Park, Jun‐Bean , Kim, Yong‐Jin , Ommen, Steve R. , Kim, Hyung-Kwan , Ommen, Steve, Choi, You‐Jung , Moon, Inki , Park, Jiesuck , Sohn, Dae‐Won

Mayo Clinic

Heart | August 5, 2019 | Volume: 105 | Issue: 24 | Pages: 1892-1897

10.1136/heartjnl-2019-315160 | PMID 31383719 Get It

Objective The hypertrophic cardiomyopathy (HCM) risk-sudden cardiac death (SCD) calculator endorsed by the 2014 European Society of Cardiology has not been independently validated in the Asians. We aimed to investigate whether the HCM Risk-SCD calculator effectively predicts SCD in Korean HCM population. Methods An observational, longitudinal cohort study was performed in 730 patients with HCM from 2007 to 2017. The primary endpoint was a composite of SCD and appropriate implantable cardioverter-defibrillator (ICD) therapy. Results During a follow-up period of 4288 person-years, 16 (2.2%) patients reached the primary endpoint. This validation study revealed a calibration slope of 0.892 and C-statistics of 0.718. The primary endpoint occurred in 1.1% (7/615), 4.6% (3/65) and 12.0% (6/50) of low-risk, intermediate-risk and high-risk groups, respectively. Although most patients (85.2%) without the primary endpoint were classified into the low-risk group, 7 of 11 SCD (63.6%) occurred in the low-risk group. In univariable and multivariable analysis, sex (woman) was significantly associated with the primary endpoint and emerged as independent predictor. The addition of sex to the HCM Risk-SCD calculator significantly improved the predictive value of the primary endpoint (net reclassification improvement 0.557, p=0.015). Conclusions In the Korean HCM population, the HCM Risk-SCD calculator had a high negative predictive value and accuracy for predicting SCD or appropriate ICD therapy, but misclassified a few patients experiencing the primary endpoint as low-risk or intermediate-risk groups.